Dr. Dubois is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8140 North Mopac
Building 3, Suite 120
Austin, TX 78759Phone+1 512-349-9889Fax+1 512-349-9559
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Dermatology, 1988 - 1991- Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1987 - 1988
The University of Texas Health Science Center at San AntonioClass of 1987
Certifications & Licensure
TX State Medical License 1995 - 2025
WA State Medical License 1991 - 1994- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis Start of enrollment: 2014 Jan 01
- Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2014 Apr 01
- Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsRoflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia
Journal of the American Academy of Dermatology. 2024-05-01 - 5 citationsOnce-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani
The British Journal of Dermatology. 2023-09-15 - 19 citationsTapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.John E. Jett, Michael McLaughlin, Mark S. Lee, Lawrence Charles Parish, Janet DuBois
American Journal of Clinical Dermatology. 2021-10-28
Press Mentions
Promising SK Drug’s Trials Enter Final PhasesMarch 3rd, 2015
Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group StudyAugust 21st, 2019
Vial Launches Innovative Dermatology CRO January 27th, 2022
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
